Development of pyogenic granuloma with strong vascular endothelial growth factor receptor-2 expression during ramucirumab treatment

The angiogenesis inhibitor ramucirumab (IMC-1121B) is a fully humanised IgG1 monoclonal antibody targeting the extracellular domain of vascular endothelial growth factor receptor 2. Ramucirumab has been approved as a second-line treatment for lung cancer. Pyogenic granuloma is an acquired, benign va...

Descripción completa

Detalles Bibliográficos
Autores principales: Ibe, Tatsuya, Hamamoto, Yoichiro, Takabatake, Mikage, Kamoshida, Shingo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2019
Materias:
Findings That Shed New Light on the Possible Pathogenesis of a Disease or an Adverse Effect
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6887457/
https://www.ncbi.nlm.nih.gov/pubmed/31776151
http://dx.doi.org/10.1136/bcr-2019-231464

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6887457/
https://www.ncbi.nlm.nih.gov/pubmed/31776151
http://dx.doi.org/10.1136/bcr-2019-231464

Ejemplares similares